ReviewJournal of Cancer2026
Regulatory roles of E3 ubiquitin ligase RNF128 in inflammatory diseases and tumors.
Review in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ring finger protein 128 (RNF128) belongs to the family of transmembrane E3 ubiquitin (Ub) ligases. It mediates substrate-specific ubiquitination as a critical post-translational modification and regulates diverse physiological activities and pathological processes. More importantly, the E3 Ub ligase RNF128 is involved in both innate and adaptive immune responses through Ub-dependent regulation of its target proteins. Dysregulation of RNF128 is associated with the occurrence and development of multiple diseases. In recent years, numerous studies have demonstrated the involvement of RNF128 in the progression of inflammatory disorders and tumors. Nevertheless, mechanistic discrepancies persist regarding its dual pro-/anti-inflammatory and pro-/anti-tumor functions. Furthermore, there remains a lack of systematic evaluation concerning the context-dependent regulatory roles of RNF128 in inflammatory responses and tumorigenesis, as well as its targeted therapeutic landscape. Accordingly, this article comprehensively reviews the structure-function relationships of RNF128, its mechanistic regulation of inflammation and tumor progression, and the existing functional controversies in colorectal cancer. It summarizes potential targeted intervention strategies and clinical translational prospects, highlights current research limitations, and proposes future investigative directions. This review aims to provide scientific references for further mechanistic exploration of RNF128 and the development of precision therapeutic strategies for related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.